Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATR | Q13535 | 20/20 | 1.00 |
| ▸ | MTOR | P42345 | 6/20 | 1.00 |
| ▸ | ATRIP | Q8WXE1 | 6/20 | 1.00 |
| ▸ | PIK3CA | P42336 | 4/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 2/20 | 1.00 |
| ▸ | TAF1 | P21675 | 2/20 | 1.00 |
| ▸ | PRKDC | P78527 | 2/20 | 1.00 |
| ▸ | PIK3R1 | P27986 | 1/20 | 1.00 |
| ▸ | ATM | Q13315 | 1/20 | 1.00 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.71 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.71 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29374072 | 1.00 | ATR (1.00) | ATRMTORATRIPPIK3CAKCNH2 | |
| SCHEMBL2511931 | 1.00 | ATR (1.00) | ATRMTORATRIPPIK3CAKCNH2 | |
| SCHEMBL23389998 | 1.00 | ATR (1.00) | ATRMTORATRIPPIK3CAKCNH2 | |
| SCHEMBL6519019 | 0.97 | ATR (0.93) | ATRMTORATRIPPIK3CAKCNH2 | |
| SCHEMBL6525114 | 0.97 | ATR (0.93) | ATRMTORATRIPPIK3CAKCNH2 | |
| SCHEMBL2511925 | 0.97 | ATR (0.93) | ATRMTORATRIPPIK3CAKCNH2 | |
| SCHEMBL2512274 | 0.97 | ATR (0.93) | ATRMTORATRIPPIK3CAKCNH2 | |
| SCHEMBL2515264 | 0.95 | ATR (0.91) | ATRMTORATRIPPIK3CAKCNH2 | |
| SCHEMBL9979381 | 0.93 | ATR (0.87) | ATRMTORATRIPPIK3CAKCNH2 | |
| SCHEMBL9979100 | 0.93 | ATR (0.87) | ATRMTORATRIPPIK3CAKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2379530-A1 | PYRIMIDINE INDOLE DERIVATIVES FOR TREATING CANCER | AstraZeneca AB (SE) | 2011-10-26 | — | — | EP | claimed |
| US-20110053923-A1 | CHEMICAL COMPOUNDS 610 | ASTRAZENECA (SE) | 2011-03-03 | — | — | US | claimed |
| WO-2010073034-A1 | PYRIMIDINE INDOLE DERIVATIVES FOR TREATING CANCER | ASTRAZENECA AB (SE) | 2010-07-01 | — | — | WO | claimed |
| EP-2379530-A1 | PYRIMIDINE INDOLE DERIVATIVES FOR TREATING CANCER | AstraZeneca AB (SE) | 2011-10-26 | — | — | EP | disclosed |
| US-20110053923-A1 | CHEMICAL COMPOUNDS 610 | ASTRAZENECA (SE) | 2011-03-03 | — | — | US | disclosed |
| WO-2010073034-A1 | PYRIMIDINE INDOLE DERIVATIVES FOR TREATING CANCER | ASTRAZENECA AB (SE) | 2010-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053923-A1 | CHEMICAL COMPOUNDS 610 | ABCG2, CYP3A7, CYP2C19 | ATR 2253/4885MTOR 954/4885ATRIP 3336/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.